PharmaMar SA suffered its second development setback in recent weeks, reporting Jan. 18 that Zepsyre (lurbinectedin) failed a Phase III clinical study in platinum-resistant ovarian cancer. The Spanish biopharma's news followed a negative opinion in Europe in December for its multiple myeloma candidate Aplidin.
PharmaMar is developing Zepsyre, a synthetic alkaloid that binds to the minor groove of DNA and causes cell perturbation theoretically...